Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astepro Nasal Spray for Early COVID-19
NCT06008860Phase 4Recruiting
- Sponsor
- University of Chicago
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Azelastine Arm with Placebo Arm (2 arms). Primary endpoints: SARS-CoV-2 Viral Load at Day 10 and COVID-19 Symptom Management at Day 10. Started Jul 2023; status: recruiting.
02
Drugs
azelastine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06008860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008860.